Daiwa Securities Group
ALNY icon

Daiwa Securities Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Daiwa Securities Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$93K – 1314
2022
Q3 		$93K Buy
+100
New +$19.1K ﹤0.01% 1008

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Daiwa Securities Group's ALNY Position: Q2 2026 in Review

Daiwa Securities Group increased its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q2 2026, buying an estimated $163K and bringing the position to 25,904 shares worth $7.8M. The position accounts for 0.02% of the portfolio, ranked #426.

Daiwa Securities Group first reported a position in ALNY in Q2 2015 and has held it in 41 quarters since. The position peaked at $10.3M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Daiwa Securities Group held 25,904 shares of Alnylam Pharmaceuticals worth $7.8M as of Q2 2026.
  • Daiwa Securities Group bought 540 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $163K.
  • Alnylam Pharmaceuticals made up 0.02% of Daiwa Securities Group's portfolio in Q2 2026, its #426 holding.
  • Daiwa Securities Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
  • Daiwa Securities Group's Alnylam Pharmaceuticals position peaked at $10.3M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.